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Abstract
Bioluminescence imaging (BLI) has shown its appeal as a sensitive technique for in vivo whole body optical imaging.
However, the development of injectable tumor-specific near-infrared fluorescent (NIRF) probes makes fluorescence imaging
(FLI) a promising alternative to BLI in situations where BLI cannot be used or is unwanted (e.g., spontaneous transgenic
tumor models, or syngeneic mice to study immune effects). In this study, we addressed the questions whether it is
possible to detect tumor progression using FLI with appropriate sensitivity and how FLI correlates with BLI measurements.
In addition, we explored the possibility to simultaneously detect multiple tumor characteristics by dual-wavelength FLI
(,700 and ,800 nm) in combination with spectral unmixing. Using a luciferase-expressing 4T1-luc2 mouse breast cancer
model and combinations of activatable and targeting NIRF probes, we showed that the activatable NIRF probes
(ProSense680 and MMPSense680) and the targeting NIRF probes (IRDye 800CW 2-DG and IRDye 800CW EGF) were either
activated by or bound to 4T1-luc2 cells. In vivo, we implanted 4T1-luc2 cells orthotopically in nude mice and were able to
follow tumor progression longitudinally both by BLI and dual-wavelength FLI. We were able to reveal different probe signals
within the tumor, which co-localized with immuno-staining. Moreover, we observed a linear correlation between the
internal BLI signals and the FLI signals obtained from the NIRF probes. Finally, we could detect pulmonary metastases both
by BLI and FLI and confirmed their presence histologically. Taken together, these data suggest that dual-wavelength FLI is
a feasible approach to simultaneously detect different features of one tumor and to follow tumor progression with
appropriate specificity and sensitivity. This study may open up new perspectives for the detection of tumors and metastases
in various experimental models and could also have clinical applications, such as image-guided surgery.
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Introduction
Both bioluminescence imaging (BLI) and fluorescence imaging
(FLI) are widely used optical modalities for non-invasive detection
of tumor progression in small animals. BLI is appealing for in vivo
whole body imaging because of its exceptional sensitivity and
almost negligible bioluminescent background [1,2,3]. However,
under certain circumstances, BLI is not applicable. For example,
BLI cannot be employed in tumor models lacking expression of
bioluminescent reporters, such as in spontaneous- or chemical-
induced cancer models. Moreover, the introduction of a foreign
reporter protein, such as luciferase, may induce an immune
response directed against the reporter protein itself in syngeneic
mouse models of cancer [4,5,6,7,8]. Finally, for clinical applica-
tions, such as image-guided surgery [9], BLI is also not applicable
as it requires genetic modification of the targeted cells.
Recent advances in the development of tumor-specific inject-
able near-infrared fluorescent (NIRF) probes make FLI a
promising alternative to BLI. The use of NIRF probes has several
advantages. For example, in the near-infrared (NIR) region (600–
900 nm), the absorption coefficient of major light absorbers in
tissues (e.g., hemoglobin and water) is minimal, which improves
the photon penetration depth. Moreover, the autofluorescence of
tissues in the NIR region is minimal, which provides a high
contrast between target and background fluorescence [10,11,12].
Currently, there are two main types of commercially available
NIRF probes. Firstly, the so-called protease-activatable probes
which can visualize tumors via activation by enzymes, such as
matrix metalloproteinases (MMPs) or cathepsins, which are over
expressed by various tumors and their surrounding stroma
[13,14,15,16,17,18]. Secondly, targeting probes which can
recognize tumor tissues by binding to specific membrane targets,
like glucose transporters (GLUTs) or epidermal growth factor
receptors (e.g., EGFR, HER2) [19,20,21,22]. These transporters
and cell-surface receptors are over expressed in many different
tumor cells because of their elevated glycolysis and proliferation
[23,24,25,26,27]. These enzyme activatable and targeting probes
were labeled with a 700 nm or 800 nm fluorophore, respectively,
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imaging. This method, with the introduction of spectral unmixing,
extends the number of measurements made in the same animal
and offers more accurate biologic observations in vivo [28].
The aim of the present study was to explore the use of FLI as a
viable and sensitive alternative to BLI. We also investigated the
possibility to simultaneously detect multiple tumor characteristics
by using FLI at two wavelengths in combination with spectral
unmixing. For this, we employed different combinations of
activatable and targeting NIRF probes in a luciferase-expressing
4T1-luc2 mouse breast cancer model and assessed the correlation
between FLI and BLI measurements.
Materials and Methods
Ethics statement
All animal experiments were approved for animal health, ethics,
and research by the Animal Welfare Committee of Leiden
University Medical Center, the Netherlands (Approval DEC
number 09050). All animals were five week-old BALB/c nu/nu
female mice (Charles River Laboratories, France) and received
humane care and maintenance in compliance with the ‘‘Code of
Practice Use of Laboratory Animals in Cancer Research’’
(Inspectie W&V, July 1999).
Cell culture
The mouse mammary gland cancer cell line, 4T1-luc2,
expressing a codon-optimized luciferase gene (luc2) was obtained
from Caliper Life Sciences (Hopkinton, MA). This cell line has
been shown to spontaneously produce highly metastatic tumors
which can metastasize to the lung, liver and lymph nodes while the
primary tumor is growing in situ [2,29,30]. The cells were
maintained in complete RPMI-1640 Medium (Gibco, Invitrogen,
Carlsbad, CA).
In vitro cell-based fluorescent assays
The specificities and sensitivities of ProSense680,
MMPSense680 (Perkin Elmer Inc., Boston, MA), IRDye
800CW 2-DG and IRDye 800CW EGF (LI-COR Biosciences,
Lincoln, NE) to detect 4T1-luc2 cells were assessed in cell-based
assays. For dose-dependent experiments, 1610
4 cells were seeded
in 96-well plates and maintained in RPMI-1640 medium at 37uC,
in a humidified incubator containing 5% CO2. After overnight
adhesion, probes with different concentrations were added to the
cell culture: 0 to 45nM for ProSense680 and MMPSense680, and
0t o1 0mM for IRDye 800CW 2-DG and IRDye 800CW EGF.
The cells were incubated with the activatable probes (ProSense680
and MMPSense680) for 24 hours. Cells were washed twice with
phosphate buffered saline (PBS) before imaging, to remove
unbound dye. For the targeting probes (IRDye 800CW 2-DG
and IRDye 800CW EGF), cells were starved for two hours in
serum-free low-glucose DMEM (Gibco, Invitrogen, Carlsbad, CA)
to elevate GLUT-1 or EGFR expression levels. Subsequently, the
IRDye 800CW 2-DG was added and the cells were incubated for
an additional two hours. For the IRDye 800CW EGF, the cells
were incubated with the probe for 15 minutes. Both assays were
then stopped and fixed for 20 minutes with 4% formaldehyde.
Cells were subsequently washed twice with PBS to remove
unbound probes. For cell amount-dependent experiment, 4T1-
luc2 cells were seeded with a serial of cell dilutions, from 2610
4 to
39 cells/well. After overnight adhesion, cells were incubated either
with 22.5nM Prosense680 or with 100nM IRDye 800CW EGF, as
described previously. The 96-well plates were scanned with the
Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln,
NE), at the 700nm and 800nm channels.
Microscopic analysis
4T1-luc2 cells were cultivated and incubated with probes
following the procedure described previously. At the end of probe
incubation, the growth medium was discarded and the cells were
washed with pre-warmed fresh medium. The carbocyanine dye
DiI, and Hoechst 33342 (Invitrogen, Carlsbad, CA) were then
added to stain the cell membrane and nucleus, respectively,
according to the manufacturer protocol. Samples with Pro-
Sense680 or MMPSense680 were imaged with a confocal TCS
SP5 microscope (Leica, Mannheim, Germany) using appropriate
laser power. Samples with IRDye 800CW 2-DG or IRDye
800CW EGF were imaged with the Nuance multispectral imaging
system (Cri, Inc., Woburn, MA) using a Xenon 75W lamp
followed by spectral unmixing [31].
In vivo optical imaging
To follow tumor growth longitudinally, 2610
4 4T1-luc2 cells
were implanted into the lateral thoracic mammary fat pad (MFP)
of the nude mice. For the tumor cell detection limit experiment,
different numbers of 4T1-luc2 cells (1610
5,5 610
4, 2.5610
4 and
1.25610
4) were implanted into four upper thoracic MFPs. The
combination of Prosense680 and IRDye 800CW EGF was
injected the day before measurement (day 0 and day 3).
Throughout tumor inoculation and imaging procedures, the
animals were anesthetized with isoflurane. For in vivo BLI,
150mg/kg of D-luciferin solution (SynChem, Inc., Elk Grove
Village, IL) in PBS in a total volume of 50 mL was injected
intraperitoneally 10 minutes prior to imaging. The animals were
imaged with the IVIS 100 imaging system (Caliper Life Sciences,
Hopkinton, MA). Regions of interest (ROI) from displayed images
were selected to cover the tumor regions and quantified with
Living Image software from Caliper Life Sciences, using protocols
as described previously [32].
For FLI, images were taken with the Maestro imaging system
(Cri, Inc., Woburn, MA), 24-hour after probe injection of either
the combination of ProSense680 (1.33nmol/100 mL in PBS) and
IRDye 800CW 2-DG (10nmol/100 mL in PBS), or the combina-
tion of MMPSense680 (1.33nmol/100 mL in PBS) and IRDye
800CW EGF (1.33nmol/100 mL in PBS). The probes were
injected intravenously in the tail vein. Each mouse was imaged
together with a control mouse without probe injection in order to
perform spectral unmixing [31]. After spectral unmixing, ROI
from displayed images were selected as described before. The
tumor-to-background ratio (TBR) was calculated by dividing the
mean fluorescence values of the tumor region by the mean
fluorescence values of the tumor border areas (Fig. 1).
For ex vivo BLI, 150mg/kg D-luciferin solution was injected into
the mice five minutes prior to necropsy. Tissues of interest were
excised and re-imaged for BLI and FLI signals. After imaging,
excised tissues were subsequently prepared for standard histopa-
thology analysis.
Histological analysis
Primary tumors and possible metastatic tissues (lungs) were
surgically removed and processed, either for paraffin-embedding
or for cryosectioning. 8 mm slices of excised tumor tissues were
scanned on the Odyssey machine using the 700nm and 800nm
channels. The tumor sections containing ProSense680 and IRDye
800CW 2-DG were processed for CathpsinB (Calbiochem,
Darmstadt, Germany) and GLUT-1 (abcam, San Francisco, CA)
antibody staining. Sections containing MMPSense680 and IRDye
Dual-Wavelength NIRF Imaging of Tumor Progression
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Inc., Heidelberg, Germany) and EGFR (abcam, San Francisco,
CA) immuno-staining, respectively. Finally, the presence of
metastases in lungs was confirmed by a pathologist in hematoxylin
and eosin (H&E) stained sections.
Statistical analysis
In order to analyze the correlation of FLI signals obtained from
the NIRF probes with BLI signals from tumor cells, Pearson’s r
test was applied for statistical analysis, as a descriptor of the degree
of linear association.
Results
In vitro characterization of different activatable and
targeting NIRF probes
Activation of ProSense680 and MMPSense680 and binding of
IRDye 800CW 2-DG and IRDye 800CW EGF by 4T1-luc2 cells
were examined. Activation/binding assays, using a fixed initial
number of cells incubated with different probe concentrations,
were performed. A dose-dependent increase in the fluorescent
signal intensity was found at increasing concentrations of each
probe (Fig. 2A and B). As shown by microscopic analysis (Fig. 2C
and D), the fluorescent signal (red) representing ProSense680 and
IRDye 800CW 2-DG was found localized specifically in the
cytosol of the cells. Similar results were found with MMPSense680
and IRDye 800CW EGF (data not shown).
Sensitivity of FLI and BLI measurements in vitro and in
vivo
In order to assess the sensitivity of FLI and BLI measurements,
celllimit detection assays wereperformed. Invitro, asshown inFig.3,
both the bioluminescent and fluorescent signals elevated with
increasing cell numbers. However, the sensitivity of BLI was found
to be superior to that of FLI. In our study, the cell detection limits
Figure 1. Schematic representation of the localization of the
signal intensity areas used to calculate TBRs. TBRs were
calculated by dividing the mean fluorescence intensity of four areas,
of the same size, located inside the tumor region (1–4) by the mean
fluorescence intensity of four areas located approximately 5 mm
outside the tumor region (background fluorescence) (5–8).
doi:10.1371/journal.pone.0031875.g001
Figure 2. In vitro NIRF probe activation/binding assays. 4T1-luc2 breast cancer cells were seeded in 96-well plates and incubated with
increasing concentrations of Prosense680 or MMPSense680 (A) and IRDye 800CW EGF or IRDye 800CW 2-DG (B) and were subsequently imaged.
Intracellular accumulation of Prosense680 (45nM; 24 h incubation) was visualized by confocal microscopy (C). Intracellular accumulation of IRDye
800CW 2-DG (10 mM; 2 h incubation) was visualized by the Nuance multispectral imaging system (D). NIRF probes, cell nuclei and membranes are
indicated in red, blue and green, respectively.
doi:10.1371/journal.pone.0031875.g002
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Prosense680and 1,250 cells/well (P,0.05)for IRDye 800CWEGF.
In vivo, cell detection limit experiments were performed with
orthotopical tumor cell implants. ProSense680 and IRDye 800CW
EGF were used for dual-wavelength FLI and compared to BLI
measurements. As shown in Fig. 4A and 4C, one day after
implantation all MFP implants, including those with the lowest cell
number (1.25610
4), were detectible with BLI. However, using
Prosense680 and IRDye 800CW EGF, the lowest detectible
number for FLI was 5610
4 cells (Fig. 4B and 4C). Moreover, four
days after implantation, all MFP cell implants could be detected
both by BLI and FLI (Fig. 4D–F).
In vivo detection of tumor progression
The ability of the four different NIRF probes to detect tumor
progression was examined in a mouse model of breast cancer.
Both BLI and FLI signals were measured at different time points of
tumor progression (day 4 to 18). Dual-wavelength images of
MMPSense680 and IRDye 800CW EGF, at different time points
of tumor progression, are shown in Fig. 5. As expected, tumors
could be detected on day 4 after cell implantation, both by BLI
and FLI. The tumor signal intensity increased up to day 18, the
final day of the experiment (Fig. 5A–C, E–G and I–K). Some
fluorescence was observed in the bladder on day 4 (Fig. 5E and I),
due to the excretion of the probes into the urine. This bladder
signal was, however, invisible at later time points of tumor
progression, as at these stages the bladder signal is superseded by
the stronger signal from the tumor. At the end of the experiment,
the mice were sacrificed and thoracic cavities were exposed and
reimaged to reveal possible metastases. As shown in Fig. 5D, H, L,
in the lungs, both BLI and FLI signals were detectible at
corresponding sites.
Histological analysis of the primary 4T1-luc2 breast tumor
revealed that it composed of actively proliferating neoplastic cells,
growing with an incomplete tumor capsule and infiltrating the
surrounding tissues (Fig. 6A). The pulmonary metastases, detected
by FLI and BLI, were confirmed histologically (Fig. 6B).
Figure 3. In vitro tumor cell detection limit studies. 4T1-luc2 cells
were seeded in 96-well plates with various initial densities (39 to 2610
4
cells per well). The next day, cells were used for BLI measurement or
incubated with either Prosense680 or with IRDye 800CW EGF and then
used for FLI measurements. Statistic significance was calculated by
determining the difference between optical signals from wells with and
without cells. The star indicates the first significant difference.
*=P,0.05; ***=P,0.0001.
doi:10.1371/journal.pone.0031875.g003
Figure 4. In vivo tumor cell detection limit studies. Different numbers of 4T1-luc2 cells were implanted orthotopically into nude mice. 1610
5,
5610
4, 2.5610
4 and 1.25610
4 cells were implanted at the upper left, upper right, lower left and lower right MFPs, respectively. BLI measurements at
day 1 and 4 are shown in panels A and D. The corresponding IRDye CW800 EGF FLI measurements are shown in panels B and E, respectively.
Quantitative analysis of the BLI and FLI measurements using both IRDye CW800 EGF and Prosense680 are shown in panels C and F.
doi:10.1371/journal.pone.0031875.g004
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EGFR, as well as the expression of MMP-9 and Cathepsin B, was
shown by immunohistochemistry (Fig. 7A–D) as well as indicated
by FLI (Fig. 7E–H).
Correlation between BLI and FLI measurements
Fig. 8 shows the growth curves of 4T1-luc2 breast tumors
detected by BLI and by FLI, using the four different NIRF probes.
The correlation plots of the BLI versus FLI signals from the
various probes are shown in Fig. 9. A significant linear relationship
was found between the obtained tumor BLI and FLI signals from
each of the four probes: Prosense680 (r=0.73, p,0.01), IRDye
800CW 2-DG (r=0.70, p,0.01), MMPSense680 (r=0.92,
p,0.0001) and IRDye 800CW EGF (r=0.88, p,0.0001).
Calculation of the tumor-to-background ratio
The calculated TBRs of the different NIRF probes on day 18,
the last day of the experiment, were: ProSense680 2.2960.38;
Figure 5. Longitudinal imaging of tumor growth by BLI and FLI. Representative images of tumor progression by BLI (A–D) and FLI utilizing
MMPSense680 (E–H) in combination with IRDye 800CW EGF (I–L) are shown. At the end of the experiment, the lungs of the tumor-bearing mice were
re-imaged and co-localizing BLI and FLI signals were observed, indicating the presence of pulmonary metastases (D, H and L).
doi:10.1371/journal.pone.0031875.g005
Figure 6. H&E stained paraffin sections of a primary tumor and of its pulmonary metastases. Panel A shows a section of a primary 4T1-
luc2 breast tumor indicating neoplastic, actively proliferating cells invading the healthy surrounding tissues. Panel B shows subpleural pulmonary
metastases of the tumor.
doi:10.1371/journal.pone.0031875.g006
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IRDye 800CW EGF 4.0260.24, respectively (Fig. 10).
Discussion
Given its high sensitivity and negligible background in living
tissues, BLI is extensively used for the non-invasive whole body
optical imaging of tumor progression in small animals. However,
in particular situations, FLI utilizing NIRF injectable probes is a
promising alternative to BLI [4,5,6,7,8]. Moreover, contrary to
BLI, FLI can be applied for clinical use. Recently we have
successfully implemented FLI in the clinic for sentinel lymph node
detection using the NIRF dye indocyanine green (ICG) [33,34]. In
the near future, injectable tumor detecting NIRF probes may enter
the clinic, for e.g. image-guided surgery, to facilitate radical tumor
resection [9].
To determine if FLI can be used as an alternative for BLI to
follow tumor progression, we employed an orthotopic mouse model
using the 4T1-luc2 breast cancer cell line. As orthotopically
implanted 4T1-luc2 breast cancer cells grow at the primary
injection site and can metastasize to various organs within 2–6
weeks, this is an excellent mouse model that closely mimics human
breast cancer [29]. Moreover, the introduction of a codon-
optimized firefly luciferase (luc2) gene into these cells strongly
increases the brightness of the bioluminescent signal, allowing for
more sensitive and early-stage non-invasive detection of the tumor
[2].
In this 4T1-luc2 model, we first examined the tumor detecting
abilities of four different NIRF probes, which are able to detect
general tumor cell characteristics. These include: increased
expression of growth factor receptors (e.g., EGFR) [25,26,27,35],
elevated glucose metabolism and up-regulated glucose transporters
(e.g., Glut-1) [23,24] and an increased tissue proteolysis by the
tumor, through upregulation of proteolytic enzymes such as
MMP-2, -9 [18,22,36] and cathepsin B and D [13,14].
In vitro, we examined the activity and binding properties of the
four NIRF probes towards 4T1-luc2 cells and observed a dose-
dependent uptake of each probe. This indicates that 4T1-luc2 cells
express both GLUTs and EGFRs and also possess MMP- and
cathepsin- activity in vitro. This is in line with previous studies
Figure 7. Immunohistological and fluorescent analysis of tumor sections. The upper panels display sections stained with antibodies against
EGFR (A), GLUT-1 (B), MMP-9 (C) and CathepsinB (D). The lower panels show the corresponding sections with FLI signals from animals injected with
IRDye 800CW EGF (E), IRDye 800CW 2-DG (F), MMPSense680 (G) or ProSense680 (H). Scale bar=2 mm.
doi:10.1371/journal.pone.0031875.g007
Figure 8. 4T1-luc2 tumor growth curve indicated by BLI and FLI. During tumor progression, from day 4 to day 18, there was a steady increase
in both BLI and FLI signal intensities.
doi:10.1371/journal.pone.0031875.g008
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cells, express GLUTs and EGFRs [37,38,39] as well as MMP- and
cathepsin- activity [40,41,42,43]. Using multispectral microscopy,
we demonstrated that the activatable as well as the targeting
probes were localized intracellularly. Consistently, Kovar et al.
previously showed that IRDye CW800 2-DG enters the cytoplasm
via internalization of the probe/receptor complex shortly after
binding to its receptor [21].
In vivo, tumor development and progression was studied using
BLI and FLI, exploiting dual-wavelength imaging of a combina-
tion of an activatable (,700nm) and a targeting (,800 nm) NIRF
probe. Tumors could be detected at an early stage of the
development (day 4) and a strong linear correlation between FLI
and BLI measurements was observed for all probes tested.
Metastases, present in the lungs, could only be detected ex vivo
both by BLI and FLI and signals co-localized. Histological
examination confirmed the presence of subpleural lung metastases.
To further examine the specificity of the NIRF probes,
immunohistochemistry was performed. Expression of GLUT-1,
EGFR, MMP-9 and Cathepsin B was found throughout the tumor
and the expression patterns closely corresponded to those obtained
with FLI. As can be appreciated from these immunohistological
and FLI data, the distribution of the examined probes is rather
inhomogeneous in this breast tumor model. The strong immuno-
stained areas of each marker coincided with the more intense
fluorescent areas. Thus, by using dual-wavelengths, combined with
Figure 9. Correlation plots of BLI against FLI signals obtained longitudinally, utilizing four different NIRF probes. The Pearson’s r
values of the NIRF probes were: Prosense680 (r=0.72, p,0.01), IRDye 800CW 2-DG (r=0.70, p,0.01), MMPSense680 (r=0.92, p,0.0001) and IRDye
800CW EGF (r=0.88, p,0.0001).
doi:10.1371/journal.pone.0031875.g009
Figure 10. TBRs of 4T1-luc2 tumors exploiting four different
NIRF probes. The TBRs, measured on the final day of the experiment,
for ProSense680, IRDye 800CW 2-DG, MMPSense680 and IRDye 800CW
EGF ranged from 2.2960.38 to 4.0260.24.
doi:10.1371/journal.pone.0031875.g010
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simultaneously. This may provide a more comprehensive image of
the tumor, as different types of tumors are often heterogeneous in
structure and molecular characteristics.
The sensitivities of both BLI and FLI in vitro and in vivo were
assessed by tumor cell detection limit experiments. In our study,
the in vitro detection limit of BLI was lower than 39cells/well. For
FLI, the detection limits were 625 and 1,250 cells/well using
Prosense680and IRDye 800CW EGF, respectively. In vivo, the
lowest cell amount (day 1) used for these experiments (1.25610
4
cells) was well within the detection limit of BLI, as expected [2].
The detection limits of FLI using IRDye 800CW EGF and
Prosense680 were approximately 5610
4 cells. Our findings
indicate that although the sensitivity of FLI is lower than that of
BLI, FLI is a reliable alternative in experimental settings where
BLI cannot be used or is not wanted.
The TBR is a ratio which expresses the specificity of a
fluorescent probe and as such it is used to discriminate between
tumor tissue and healthy tissue. IRDye 800CW EGF had the
highest TBR (TBR=4.02). The TBRs of the other NIRF probes
examined in this study were all above two. Probes with a TBR
above two can be considered applicable for clinical applications
such as image-guided surgery [9,44].
Conclusions
FLI using various injectable tumor specific NIRF probes is a
feasible approach to follow tumor growth and to detect metastasis.
This was shown in sensitivity and specificity studies and by a linear
correlation between the FLI and BLI tumor signals. Moreover,
dual-wavelength imaging using spectral unmixing enables the
simultaneous detection of multiple tumor characteristics. Taken
together, dual-wavelength imaging of tumor progression by
activatable and targeting NIRF probes is useful in pre-clinical
studies and can possibly be translated towards clinical applications,
such as image-guided surgery.
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